Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Enhance Biotech, Inc.
Company reports unique mechanism of action for cellulite treatment
September 1st, 2004
Enhance Biotech, Inc., (EBOI), a developer of a portfolio of products focused on lifestyle drugs, has reported the discovery of a combination mechanism of action for the company's anticellulite treatment LI303. The discovery, elucidated in vitro, points to several distinct areas of activity for LI303 which, collectively, influence the behavior of cells critical to the development and establishment of the cellulite condition. The new data helps to explain the molecular basis for the promising cosmetic effects reported in early-stage research, and differentiates the compound from currently available treatments by transiently tightening the surface of the skin. ...
Source: Biotech Week (2004-09-01)
|
